Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Tissue Engineering CoTSE:7774 -0.23%58 Days Payable is 12.65 as of Mar. 2026, which is 52% below its 10-year median of 26.16. GuruFocus rates TSE:7774 with a GF Score™ of 58/100 and a GF Value™ of 円505.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Japan Tissue Engineering Co ranks worse than 93.04% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Days Payable falls into.
Japan Tissue Engineering Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co (TSE:7774) has a Days Payable of 12.65 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Japan Tissue Engineering Co and its competitors. This is 52% below median its historical median of 26.16. Over the past decade, Japan Tissue Engineering Co's Days Payable has ranged from 8.59 to 56.94. According to the industry distribution chart, Japan Tissue Engineering Co ranks #655 out of 704 companies in the Biotechnology industry, placing it in the top 93%.
Is Japan Tissue Engineering Co's Days Payable too high?
Japan Tissue Engineering Co's current Days Payable of 12.65 is 52% below median its 10-year median of 26.16. Over the past 10 years, this metric has ranged from a low of 8.59 to a high of 56.94. The Biotechnology industry median Days Payable is 110.01. Japan Tissue Engineering Co's value of 12.65 is 88.5% below this industry median. Based on the distribution chart, Japan Tissue Engineering Co ranks #655 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Japan Tissue Engineering Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #655 out of 704 companies for Days Payable. This places Japan Tissue Engineering Co in the lower half of its industry. The industry median Days Payable is 110.01. Japan Tissue Engineering Co's value of 12.65 is 88.5% below this benchmark. Historically, Japan Tissue Engineering Co's own Days Payable has ranged from 8.59 to 56.94 over the past decade. While the company's 10-year median is 26.16 vs. the industry median of 110.01, Japan Tissue Engineering Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Tissue Engineering Co's current Days Payable of 12.65 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Days Payable is 12.65, which is 52% below median its own 10-year median of 26.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.19, compared to a current price of 円860.00 — trading 70.2% above its estimated fair value. The current Days Payable is 12.65, which is 52% below median its 10-year median of 26.16 and 88.5% below the Biotechnology industry median of 110.01. Japan Tissue Engineering Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Days Payable is 12.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円860.00 is trading 70.2% above its estimated GF Value™ of 円505.19.
GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.
Key valuation signals for TSE:7774:
Days Payable: 12.65 (52% below median its 10-year median of 26.16)
GF Value™: 円505.19 vs. price of 円860.00 (70.2% above fair value)
Industry Position: 88.5% below the Biotechnology median (#655 of 704)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
58GF Score
Get the complete analysis for TSE:7774
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
